Coya Therapeutics, Inc. (COYA) announced that the Alzheimer's Drug Discovery Foundation has purchased 603,136 shares of the company's common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million. The ADDF's mission is to rapidly accelerate the development of drugs to prevent, and treat Alzheimer's disease and related dementias, including FTD.
Coya's lead therapeutic candidate, COYA 302, is being evaluated in multiple neurodegenerative diseases, including FTD. The company plans for this equity investment to help fund the development of COYA 302 in a planned Phase 2 trial in FTD.
Shares of Coya Therapeutics are up 6% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.